Sodium Glucose Co-Transporter 2 Inhibitors and Cardiovascular Event Protections: How Applicable Are Clinical Trials and Observational Studies to Real-World Patients?

BMJ Open Diabetes Research and Care- United Kingdom

doi 10.1136/bmjdrc-2019-000742

Full Text

Abstract

Available in

Date

Authors

Publisher

BMJ

Related search

Pdb1 - Acute Renal Outcomes With Sodium Glucose Co-Transporter 2 Inhibitors- Real World Data Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Sodium-Glucose Co-Transporter Type-2 Inhibitors: Pharmacology and Peri-Operative Considerations

Anaesthesia
AnesthesiologyPain Medicine
2018English

Sodium–glucose Co-Transporter 2 Inhibitors: Think Twice About Diabetic Ketoacidosis

2018English

Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through?

Anaesthesia
AnesthesiologyPain Medicine
2019English

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally

US Endocrinology
EndocrinologyMetabolismDiabetes
2017English

Does Gender Influence the Cardiovascular Benefits Observed With Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors? A Meta-Regression Analysis

Cardiology and Therapy
2016English

Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure

Circulation Reports
2020English

Sodium-Glucose Co-Transporter 2 Inhibitors in the Peri-Operative Period: A Warning to All Clinicians

BJU International
Urology
2019English

Clinical Relevance Between Sodium-Glucose Co-Transporter 2 Inhibitors and Lipid Profiles in Asian Patients With Type 2 Diabetes Mellitus: A Systematic Review With a Meta-Analysis of Randomized Controlled Trials

Journal of Pharmaceutical Health Care and Sciences
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy